MNOVNasdaqPharmaceutical PreparationsFiscal year ends December 31

MEDICINOVA INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.40−0.02 (-1.41%)

Close on Oct 19, 2026

Market cap: $68.91M
P/E (TTM): –
Dividend yield: –

MEDICINOVA INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	0.41	–	1.00	–	4.04	–	–	–	–	–	–	–	0.00	0.80	–	–	–	–	–	–
Research & Development	6.70	6.80	5.30	8.70	8.10	7.10	5.70	5.30	3.90	3.10	2.70	2.90	2.70	4.50	7.78	9.71	11	–	–	–
General & Administrative	6.16	5.48	5.24	5.48	5.72	6.69	7.95	9.96	8.80	7.36	5.81	5.96	6.66	6.73	8.32	8.17	10	–	–	–
Operating Expenses	14	13	11	15	14	14	14	16	13	11	8.82	9.22	10	12	16	18	21	–	–	–
Operating Income	-13	-13	-9.90	-15	-10	-14	-14	-16	-13	-11	-8.82	-9.22	-4.02	-11	-16	-18	-21	–	–	–
Interest Expense	–	–	–	–	–	–	–	–	0.00	0.00	0.00	0.00	–	–	1.60	1.77	0.24	–	–	–
Interest & Investment Income	1.30	1.67	1.83	0.81	0.14	0.36	1.15	0.94	0.15	0.07	–	–	–	–	–	–	–	–	–	–
Income from Equity Investments	–	–	–	–	–	–	–	0.02	0.00	-0.03	-0.03	0.00	0.01	–	–	–	–	–	–	–
Other Non-Operating Income	-0.01	-0.04	-0.50	-0.25	-0.06	-0.04	-0.05	-0.02	-0.03	-0.05	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	0	0	0	0	0	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	-0.45	-0.12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0	0.00	0.00	–	0.00	–	–	–	–	–	–	–	0.00	0.00	–	0.00	-0.01	–	–	–
Pretax Income	-12	-11	-8.57	-14	-10	-14	-13	-15	-13	-11	-8.84	-9.20	-4.02	-11	-18	-20	-20	–	–	–
Income Tax Expense	0.01	0.01	0.00	0.00	0.00	0.00	0.01	0.01	-1.74	0.00	0.01	0.00	0.00	0.01	0.01	0.01	0.01	–	–	–
Net Income incl. Noncontrolling Interests	-12	-11	-8.57	-14	-10	-14	-13	-15	-11	-11	–	–	–	–	–	–	–	–	–	–
Net Income	-12	-11	-8.57	-14	-10	-14	-13	-15	-11	-11	-8.85	-9.20	-4.03	-11	-18	-20	-20	-22	-49	-36
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	-9.20	-4.03	-11	-18	-20	-20	–	–	–
EPS (Basic)(per share)	-0.24	-0.23	-0.17	-0.29	-0.21	-0.31	-0.30	-0.36	-0.32	-0.33	-0.33	-0.38	-0.19	-0.66	-1.20	-1.63	-1.68	–	–	–
EPS (Diluted)(per share)	-0.24	-0.23	-0.17	-0.29	-0.21	-0.31	-0.30	-0.36	-0.32	-0.33	-0.33	-0.38	-0.19	-0.66	-1.20	-1.63	-1.68	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	49	49	49	49	49	44	43	41	35	33	27	24	21	17	15	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	49	49	49	49	49	44	43	41	35	33	27	24	21	17	15	–	–	–	–	–
EBITDA	-13	-13	-9.88	-15	-10	-14	-14	-16	-13	-11	-8.80	-9.18	-3.92	-11	-16	-18	-21	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -1287.4%
Net margin: -1168.2%
Return on equity, FY2025: -25.5%

Financial strength

Current ratio: 8.75
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 858.3%

Valuation

P/E ratio: –
Price to sales: 74.86
Price to book: 1.85
Dividend yield: –